Marksans Pharma will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution from UK MHRA. Powered by Capital Market - Live News

Marksans Pharma announced USFDA final approval of the Company`s wholly owned subsidiary Marksans Pharma Inc.`s Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, of Kenvue Brands LLC (Kenvue) NDA - 019860. Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea.Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its following products from UK MHRA: 1. Mefenamic Acid 250 mg Film-Coated Tablets 2. Mefenamic Acid 500 mg Film-Coated TabletsPowered by Capital Market - Live News

Net profit of Marksans Pharma rose 1.58% to Rs 98.25 crore in the quarter ended September 2025 as against Rs 96.72 crore during the previous quarter ended September 2024. Sales rose 12.23% to Rs 720.41 crore in the quarter ended September 2025 as against Rs 641.92 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales720.41641.92 12 OPM %20.0622.87 - PBDT160.25144.11 11 PBT133.33124.60 7 NP98.2596.72 2 Powered by Capital Market - Live News